Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07277257 · ClinicalTrials.gov registry record · Phase 4
Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome
A Phase 4 study of Sjogren Syndrome With Keratoconjunctivitis, sponsored by Center For Sight.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 35
- Enrollment target
- 1
- Study location
NCT07277257 is a Phase 4 study of Sjogren Syndrome With Keratoconjunctivitis that is actively recruiting participants, run by Center For Sight. The registered enrollment target is 35 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07277257, a Phase 4 study of Sjogren Syndrome With Keratoconjunctivitis, is actively recruiting participants, sponsored by Center For Sight.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 35 participants
- Enrollment target
- 1
- Study location
Study Summary
This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.
Conditions Studied
Interventions
- DRUG TRYPTYR (Acoltremon ophthalmic solution 0.003%)
Study Locations (1)
Florida
- Center For Sight - Venice
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2025-12-02 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07277257
The ClinicalTrials.gov registry entry for NCT07277257 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Center For Sight, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Sjogren Syndrome With Keratoconjunctivitis appearing as the primary indexed condition, and to 1 intervention - of which TRYPTYR (Acoltremon ophthalmic solution 0.003%) is the first listed.
NCT07277257 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07277257 about?
NCT07277257 is a clinical study titled "Evaluating a New Therapy for Dry Eye in Patients With Sjögren's Syndrome". This study will evaluate the effect of TRYPTYR in patients with Sjögren's syndrome-related dry eye disease. The goal is to determine whether TRYPTYR can improve symptoms and signs of dry eye in this specific patient population.
What is the current status of trial NCT07277257?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 35 participants. The study started on 2025-12-02. Estimated completion is 2026-12-31.
What conditions does trial NCT07277257 study?
This clinical trial studies the following conditions: Sjogren Syndrome With Keratoconjunctivitis.
What interventions are being tested in trial NCT07277257?
The interventions under investigation include: TRYPTYR (Acoltremon ophthalmic solution 0.003%) (DRUG).
Who is sponsoring clinical trial NCT07277257?
This trial is sponsored by Center For Sight, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07277257 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.